Here's a basket of top investments to consider for your TFSA in 2025 from low risk to high risk. The post Top Investments to ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. ABBV stock, with 24% returns ...

With the shares kicking off 2025 with a solid 8% gain year to date, some investors may wonder -- can the rally keep going, and is AbbVie stock a buy right now? Here's what you need to know.

AbbVie continued to benefit from strong sales growth for Rinvoq and Skyrizi. The company’s outlook was also better than the estimates, faring well for its stock. Separately, see What’s Next ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Despite intense competition and potential regulatory uncertainties, ABBV stock's intrinsic value calculation shows a 15% upside, further supporting the bullish outlook. AbbVie is one of the ...

Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...